Nicole DeFeudis

A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. https://t.co/A1AvtyZUbc

Trump's NIH pick Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing on Wednesday. The @endpts crew has minute-by-minute updates here: https://t.co/xIm43lLgE6

Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients. https://t.co/HXY0qFCFyl

This just in: A federal judge in Massachusetts extended a temporary nationwide block on the NIH’s 15% cap on indirect cost reimbursements for grant recipients. Read more in our blog: https://t.co/tuXthu4mVo

An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it. https://t.co/xhXRrBG0V5

Takeda CEO Christophe Weber will step down next June. Julie Kim, the current president of Takeda’s US business unit, will succeed Weber and will be the company’s first female CEO. https://t.co/oaH85Tv5Gm

My Endpoints colleagues shared minute-by-minute updates on the Senate confirmation hearing for Robert F. Kennedy Jr. today. Check it out here: https://t.co/cZBZBh8bSb

The Trump administration said it will consider “opportunities to bring greater transparency” to the Medicare drug price negotiation process under the Inflation Reduction Act. CMS said it intends to get input from stakeholders. https://t.co/z9sukcPyjT

AstraZeneca and Daiichi Sankyo redefined how breast cancer patients are classified when Enhertu was approved for HER2-low patients. Now they're expanding to "ultralow" patients. https://t.co/srcetWd5ll

Novo Nordisk is asking a federal appeals court to hurry up on its case challenging the Inflation Reduction Act’s drug pricing provisions. https://t.co/UHYq1cpELb

RT @endpts: Exclusive: Biogen will cut jobs in its research unit to refocus on external opportunities and a streamlined preclinical portfol…

AstraZeneca says it plans to participate in another round of Medicare negotiations under the IRA. But a company executive told me it's dealing with a whole new set of considerations this time around: https://t.co/GX4NpKaNyd

The @endpts Weekly has a new look! If you haven't already, sign up here to get our weekly recap of can't-miss biopharma news in your inbox on Saturday mornings: https://t.co/lkZlKnbKRW https://t.co/uIjDVG7Gfy

The pharma industry’s DC-based lobbying group urged the federal government on Friday to get on board with alternative models for 340B drug price discounts. https://t.co/DopccxQ3kP

RT @ArmstrongDrew: Recapping the last 24 hours of Pfizer-Starboard drama: Earlier today, @endpts broke the news of how a blank, seemingly…